RGXEarnings•prnewswire•
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
Sentiment:Positive (70)
Summary
RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026 Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous guidance Clemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by prnewswire